Drug intelligence / Profile preview

BPI-2361

Development stage: Preclinical
Lead developer: Beta Pharma
Modality: Small Molecules

Overview

BPI-2361 is a self-developed, highly effective small molecule inhibitor targeting the KRAS G12C mutation. The KRAS gene is one of the most frequently mutated oncogenes in human cancers, implicated in approximately 20–30% of all cases. The G12C mutation is particularly prevalent in non-small cell lung cancer (NSCLC), as well as colorectal and appendix cancers. BPI-2361 has demonstrated potent inhibition activity against KRASG12C, with efficacy comparable to leading compounds such as AMG 510 (sotorasib). It is being developed primarily for solid tumors driven by this specific genetic alteration[1][2][4].

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on BPI-2361.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-2361.

Explore the full profile